FDC Q4 FY26 Revenue up 18.9% to ₹585 Cr; PAT up 167.4%

FDC Limited announced its financial results for Q4 FY26 and the full year FY26. For Q4 FY26, revenue from operations grew 18.9% year-on-year to ₹585 crores. EBITDA surged 97.0% to ₹106 crores, with margins improving to 18.2% from 11.0% in the prior year. Profit After Tax (PAT) increased by 167.4%. All three business segments achieved healthy growth: Domestic Formulations grew 8.5%, Export Formulations 99.3%, and API business 38.6%. The US business delivered strong performance, with revenue from supplies up 165.1%. For the full year FY26, revenue from operations was ₹2,171 crores, a 3.0% growth, and EBITDA margin improved to 15.9%. The company also received USFDA approval for Fluconazole Tablets during the quarter.